Company / R&D Expense
Aquestive Therapeutics, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$17.2M
FY2025
5-year range
$13.1M / $20.3M
FY2021-FY2025
Trend
-15.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 8 years, ranging from $13M in FY2023 to $23M in FY2019.
Based on SEC 10-K filings.
$17M in FY2025 with a 5-year CAGR of -3.5%.
Improved from $13M to $17M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -0.6%
- 5-Year CAGR
- -3.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -3.5%, indicating a declining trend.
- In FY2025, r&d expense decreased 15.2% year-over-year.
- Peak r&d expense was recorded in FY2019.
- Lowest r&d expense in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.2M | -15.2% |
| FY2024 | $20.3M | +54.8% |
| FY2023 | $13.1M | -25.0% |
| FY2022 | $17.5M | -12.1% |
| FY2021 | $19.9M | -3.3% |
| FY2020 | $20.6M | -11.0% |
| FY2019 | $23.1M | +4.4% |
| FY2018 | $22.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026